Aspyre Clinical Test

Hear experts address the gaps and limitations of CGP by using innovative simplified genomic profiling solutions that work for challenging samples not analyzable by CGP.

This case illustrates the significant advantages of using Biofidelity’s Aspyre Clinical Test for Lung in managing NSCLC.

This case illustrates the significant advantages of using Biofidelity’s Aspyre Clinical Test for Lung in managing NSCLC.

A new study from Biofidelity is examining how its Aspyre technology can bridge the gaps in clinical care that prevent early-stage NSCLC patients from receiving molecular profiling.

See the workflow for Aspyre Clinical Test in the video below.

Simple, fast, reliable detection of NSCLC biomarkers from tissue or blood within 2 days.

Learn more about how Aspyre Clinical Test for Lung overcomes your challenges with QC failures, QNS, and rapid turnaround time.

Discover Aspyre Clinical Test, a breakthrough in lung cancer testing. Our technology provides physicians with actionable results within days of diagnosis, enabling rapid identification of the best treatment options.

Learn about the emerging trends in biomarker testing for early-stage non-small cell lung cancer (NSCLC) and the impact of minimal residual disease (MRD) testing.

The 2023 ASCO meeting showcased impressive clinical advances in cancer treatment, but a study on liquid biopsy technology raises questions about false positive results and clinical management. Is this good enough for patients?

Biofidelity's VP of Strategic Marketing, Anjana Bhattacharya, shares her thoughts from ASCO 2023 on how the complexity of NGS-based biomarker testing and contemporary genomic biomarker testing rates reveal persistent gaps in NSCLC patient care.

Read about what DNA Day means to Biofidelity in this blog post from our Co-founder & CEO.

Read about Crystal Cuadra-Cutler's diagnosis of non-small cell lung cancer (NSCLC) and how important biomarker testing was in her recovery.